This is the authors' abstract. We don't add key points for this paper.
These data suggest that perampanel is an orally active, noncompetitive, selective AMPA receptor antagonist with potential as a broad spectrum antiepileptic agent.
No takes yet. Share an insight, caveat, or question.
Hanada et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: